Gilles A. Salles

Gilles Salles practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Gilles Salles' NPI, 1083389290, was assigned on August 10, 2021. Gilles Salles graduated from Université Claude Bernard Lyon in 1989. Gilles Salles holds New York license 312234.

Gilles Salles' primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Gilles Salles' primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Gilles Salles practices. Vendor and product names are available with a free account.

Hematology and oncology is Gilles Salles' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Gilles Salles is licensed in New York.

CMS data shows 387 Medicare services from Gilles Salles across 3 procedure codes in 2024, all of them office visits, for 176 Medicare patients. Medicare paid $46,036 for them. Every service was in an office.

CMS counts 176 Medicare patients who saw Gilles Salles in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gilles Salles' median patient age at 72, with 46% women.

In 2024, Gilles Salles wrote 106 Medicare Part D claims for 29 patients. 78% of them were for generic drugs. CMS names the drug for 42 of them, across 1 drug with 11 or more claims each, at $545 in total drug cost. In 2023, CMS named 127 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Gilles Salles for performance year 2024, reported as part of a group. Gilles Salles accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Gilles Salles as offering telehealth.

Dmand AI links 538 papers to Gilles Salles, published from 2008 to 2025. 2021 was the busiest year, with 44. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Rituximab and Lymphoma, Large B-Cell, Diffuse. Gilles Salles has published most often in Blood. Gilles Salles' most frequent co-authors are Maria Lia Palomba, MD, Thomas M. Habermann, MD and Gunjan Lalitchandra Shah, MD.

Dmand AI links Gilles Salles to 21 clinical trials, 7 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell and Lymphoma, B-Cell. Memorial Sloan Kettering Cancer Center sponsors the most, 6. Open Payments lists research payments to Gilles Salles that name 2 trials.

CMS Open Payments shows 189 general payments to Gilles Salles from 25 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 78% of the total. Genentech, Inc. paid the most, $67,966. It also lists 11 research payments totaling $6,430 from 2021 to 2025, naming 2 clinical trials.

Dmand AI lists 4 awards for Gilles Salles, most recently T Howard Lee Keynote Lecture in 2023.

Gilles Salles graduated from Université Claude Bernard Lyon in 1989.

Gilles Salles is in network with 12 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.